CRISPR Therapeutics AG (CRSP) Stock Analysis & Winston Score

CRISPR Therapeutics is a biotech company that uses a gene-editing tool called CRISPR-Cas9 to develop medicines that fix or replace faulty genes in the human body. Its main focus is on serious diseases like sickle cell disease, beta thalassemia, and certain cancers. Its most advanced product, Casgevy, was developed with partner Vertex Pharmaceuticals and became one of the first approved CRISPR-based gene-editing therapies in the world. The company makes money primarily through collaboration agreements and milestone payments from partners, though Casgevy is now commercially available and generating early product revenue. CRISPR Therapeutics is headquartered in Switzerland and has operations in the United States. The negative margins reflect the reality that it still spends far more on research than it earns — a common situation for early-stage biotechs. The key growth driver is expanding Casgevy's patient uptake and advancing its pipeline of cancer and diabetes treatments, while the main risk is that gene therapies are expensive and complex to deliver at scale.